Vertex Pharmaceuticals (VRTX)
Develops cystic fibrosis medicines, gene-edited cell therapy, and non-opioid pain treatment.
Something off on this page? Send us feedback.
Develops and sells cystic fibrosis medicines led by TRIKAFTA/KAFTRIO and ALYFTREK, plus CASGEVY gene-edited cell therapy and JOURNAVX non-opioid acute-pain treatment. CF products still generate nearly all revenue, alongside a broader pipeline in kidney disease, pain, diabetes, and other serious conditions.
Develops and commercializes medicines for serious diseases, anchored by cystic fibrosis therapies. The CF portfolio spans TRIKAFTA/KAFTRIO, once-daily ALYFTREK, and earlier KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI, with sales across the U.S. and more than 60 countries.
Extends beyond CF through CASGEVY, an ex vivo CRISPR/Cas9 cell therapy for sickle cell disease and transfusion-dependent beta thalassemia, and JOURNAVX, a non-opioid pain-signal inhibitor for acute pain. Kidney disease, type 1 diabetes, neuropathic pain, myotonic dystrophy, and additional CF programs make up much of the clinical pipeline.
CF medicines still generate nearly all product revenue, while newer products remain early in launch. Access depends on regulatory approvals and reimbursement agreements across national markets, and commercial supply relies partly on third-party manufacturers.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 1, 2026 | Morgan Stanley | Target | Target: $616 | Target: $665 |
| Sep 1, 2026 | Goldman Sachs | Initiate | Rating: —Target: $598 | Target: $653 |
| Aug 11, 2026 | Bernstein | Reiterate | Rating: —Target: $572 | Target: $608 |
| Aug 10, 2026 | Wolfe Research | Reiterate | Rating: —Target: $576 | Target: $562 |
| Aug 5, 2026 | Truist Financial | Target | Target: $560 | Target: $565 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.85B · Total debt $1.98B · Total assets $27.42B · Shareholders' equity $20.25B
- Revenue
- $3.33B
- Operating income
- $1.25B
- Net income
- $1.10B
No dividends on record.
| Institutions | 96.07% | 243.49M shares | |
|---|---|---|---|
| 1,821 holders · as of Jun 30, 2026 | |||
| Insiders | 0.22% | 568.2K shares | |
| 23 holders · as of Sep 10, 2026 | |||
| Other | 3.71% | 9.40M shares | |
| remainder | |||
253.46M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Capital World InvestorsInstitution | 10.30% | 26.12M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 9.51% | 24.11M | as of Jun 30, 2026 |
Capital Research Global InvestorsInstitution | 7.69% | 19.49M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.54% | 16.58M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.68% | 11.87M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 2, 2026 | Duncan McKechnie | officer: EVP, Chief Commercial Officer | −1,541 | $519.00 |
| Jul 2, 2026 | Ourania Tatsis | officer: EVP, Chief Reg. & Quality Off. | −1,500 | $524.99 |
| Jul 1, 2026 | Joy Liu | officer: EVP and Chief Legal Officer | −828 | $502.71 |
| Jun 26, 2026 | Carmen Bozic | officer: EVP and CMO | −596 | $482.50 |
| Jun 18, 2026 | Carmen Bozic | officer: EVP and CMO | −1,020 | $462.17 |
- Sionna Therapeutics
First-in-class NBD1 stabilizers challenging Vertex CF modulator dominance
- Eli Lilly
NaV1.8 non-opioid pain pipeline via SiteOne acquisition contests Journavx
- Regeneron
Rare-disease biopharma peer competing for pipeline, capital, and talent
- Beam Therapeutics
Base-editing platform for next-gen SCD/beta-thal gene therapy without DNA breaks
- Editas Medicine
AsCas12a gene-editing platform in Phase 1/2/3 trials for SCD and beta-thal
- Sana Biotechnology
iPSC-derived islet cell therapy targeting T1D cure without immunosuppression
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | $522.20 | +2.25% | $129.62B | 29.7 | 27.2 | 10.3 | +12.5% |
| Sionna Therapeutics | $6.04 | +0.59% | $270.9M | — | — | — | — |
| Eli Lilly | $1,169.03 | +0.36% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Regeneron | $807.47 | +1.17% | $82.23B | 19.7 | 13.3 | 5.3 | +16.7% |
| Beam Therapeutics | $26.09 | +3.29% | $2.60B | — | — | 16.7 | −94.2% |
| Editas Medicine | $2.88 | +1.59% | $434.3M | — | — | 9.2 | +232.3% |
| Sana Biotechnology | $3.19 | +2.74% | $862.7M | — | — | — | — |
| Median | 29.4 | 21.0 | 11.5 | +32.2% |